Chronic myelogenous leukemia (CML) is a disorder of bone marrow characterized by a prolonged period of relative quiescence that eventually leads to an acute phase of leukemia and death. The only curative form of therapy for CML is an allogeneic bone marrow transplant. Allogeneic transplants are successful in treating CML because of several factors. The conditioning regimen decreases the burden of tumor cells in the recipient and T-lymphocytes and perhaps NK cells from the donor are important in destroying residual leukemia cells left after the conditioning treatment. Whether these T- lymphocytes are specifically recognizing tumor targets or a part of the overall process of graft-versus-host disease is not clear. In this proposal, I plan to produce T cell lines and clones from the donor that specifically recognize the recipient CmL cells in vitro. The long- term goal of the project are to elucidate the epitopes presented by the CML cells that are specifically recognized by these T cell clones. I will use molecular techniques to produce CML cDNA libraries that will be screened for recognition by the CML-specific T cell clones. In addition, I will elute peptides off CML cells from class I and class II MHC molecules using acid elution and high performance liquid chromatography. The identification of tumor-specific or tissue- specific epitopes from CML cells may allow for the production of a peptide vaccine as an adjunct to the treatment of this disease. Additionally, the identification of CML-specific T cells may allow for a more rationale approach to the use of the graft-versus-leukemia effect in allogeneic bone marrow transplantation.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Chemical Pathology Study Section (CPA)
Program Officer
Poland, Alan P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
Public Health & Prev Medicine
Schools of Medicine
New York
United States
Zip Code
Wu, Jing; Omene, Coral; Karkoszka, Jerzy et al. (2011) Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer. Cancer Lett 308:43-53
Yang, Chengfeng; Wu, Jing; Zhang, Ronghe et al. (2005) Caffeic acid phenethyl ester (CAPE) prevents transformation of human cells by arsenite (As) and suppresses growth of As-transformed cells. Toxicology 213:81-96
Pelle, Edward; Huang, Xi; Mammone, Thomas et al. (2003) Ultraviolet-B-induced oxidative DNA base damage in primary normal human epidermal keratinocytes and inhibition by a hydroxyl radical scavenger. J Invest Dermatol 121:177-83
Choudhury, Sujata; Zhang, Ronghe; Frenkel, Krystyna et al. (2003) Evidence of alterations in base excision repair of oxidative DNA damage during spontaneous hepatocarcinogenesis in Long Evans Cinnamon rats. Cancer Res 63:7704-7
Li, Xiaolu; Eckard, Jonathan; Shah, Rajendra et al. (2002) Interleukin-1alpha up-regulation in vivo by a potent carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) and control of DMBA-induced inflammatory responses. Cancer Res 62:417-23
Huang, X; Powell, J; Mooney, L A et al. (2001) Importance of complete DNA digestion in minimizing variability of 8-oxo-dG analyses. Free Radic Biol Med 31:1341-51
Huang, M T; Ma, W; Yen, P et al. (1996) Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in mouse skin and the synthesis of DNA, RNA and protein in HeLa cells. Carcinogenesis 17:761-5
Bhimani, R S; Zhong, Z; Schleifer, E et al. (1995) Human promyelocytic leukemia cells (HL-60): a new model to study the effects of chemopreventive agents on H2O2 production. Cancer Detect Prev 19:292-8
Frenkel, K; Wei, L; Wei, H (1995) 7,12-dimethylbenz[a]anthracene induces oxidative DNA modification in vivo. Free Radic Biol Med 19:373-80
Frenkel, K; Karkoszka, J; Cohen, B et al. (1994) Occupational exposures to Cd, Ni, and Cr modulate titers of antioxidized DNA base autoantibodies. Environ Health Perspect 102 Suppl 3:221-5

Showing the most recent 10 out of 35 publications